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A B S T R A C T
Background
Keratoconus is an ectatic (weakening) disease of the cornea, which is the clear surface at the front of the eye. Approximately 10%
to 15% of patients diagnosed with keratoconus require corneal transplantation. This may be full-thickness (penetrating) or partial-
thickness (lamellar).
Objectives
To compare visual outcomes after deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty for keratoconus, and to
compare additional outcomes relating to factors which may contribute to poor visual outcomes (e.g. astigmatism, graft rejection and
failure).
Search methods
We searched a number of electronic databases including CENTRAL, PubMed and EMBASE without using any date or language
restrictions.We last searched the electronic databases on 31October 2013.We also handsearched the proceedings of several international
ophthalmic conferences.
Selection criteria
We included all randomised controlled trials (RCTs) comparing the outcomes of DALK and penetrating keratoplasty in the treatment
of keratoconus.
Data collection and analysis
Two authors assessed trial quality and extracted data independently. For dichotomous data (graft failure, rejection, achievement of
functional vision) results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). For continuous data (postoperative
best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), keratometric astigmatism and spherical equivalent) results were
expressed as mean differences (MDs) and 95% CIs.
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Main results
We identified two completed studies, with a total of 111 participants (n = 30 and n = 81), both conducted in Iran, that met our
inclusion criteria. Participants had moderate to severe keratoconus pre-operatively and were randomly allocated to receive either DALK
or penetrating keratoplasty. Only one eye of each participant was treated as part of the trials. The smaller study had 12 month follow-up
data for all participants. For the larger study, four DALK surgeries had to be abandoned due to technical failure and visual and refractive
outcomes were not measured in these participants. Follow-up length for the remaining 77 participants ranged from 6.8 to 36.4 months,
with all 77 followed for at least three months post-suture removal. Details of the randomisation procedure were unavailable for the
smaller study and so sensitivity analyses were conducted to determine if the results from this study had affected the overall results of
the review.
Neither of the included studies reported a difference between groups on any of themeasures of post-graft visual achievement, keratometric
astigmatism or spherical equivalent. A single case of graft failure in a penetrating keratoplasty was reported. No postoperative graft
failures were reported in the DALK group of either study.
Instances of graft rejection were reported in both groups, in both studies. The majority of these cases were successfully treated with
steroids. The data, which related to all cases in each study - given that the four cases that did not go ahead as planned had already
technically failed without presence of rejection - showed that rejection was less likely to occur in DALK (odds ratio (OR): 0.33, 95%
confidence interval (CI) 0.14 to 0.81, GRADE rating: moderate).
Results of the sensitivity analysis indicated that inclusion of the Razmju 2011 study did not bias the results with regards to rejection
episodes. While sensitivity analysis showed altered results with regards to failure rates, the data available from the Javadi 2010 study
alone had a very wide 95% CI, suggesting an imprecise estimate. Therefore, even after removal of the Razmju 2011 data, it is still
difficult to draw conclusions regarding superiority of one technique over another with regards to graft failure.
DALK was unable to be completed as planned in four cases and in a further three cases, complications during dissection required
further intervention. Other adverse events, of varying severity, were reported in both intervention groups with similar frequency. For
both types of surgery, these included postoperative astigmatism, steroid induced ocular hypertension and persistent epithelial defects.
In recipients of DALK, one participant had interface neovascularisation (a proliferation of blood vessels where the host and donor
cornea come together) and one had wrinkling of Descemet’s membrane, the basement membrane separating the corneal stroma from
the corneal endothelium. In the penetrating keratoplasty groups, one participant required graft resuturing and one had an atonic pupil,
a condition in which the pupil dilates and is non-reactive.
Overall, the quality of the evidence was rated as very low to moderate, with methodological limitations, incomplete data analysis and
imprecision of findings, as well as high risk of bias in several areas for both studies.
Authors’ conclusions
We found no evidence to support a difference in outcomes with regards to BCVA at three months post-graft or at any of the other time
points analysed (GRADE rating: very low). We also found no evidence of a difference in outcomes with regards to graft survival, final
UCVA or keratometric outcomes. We found some evidence that rejection is more likely to occur following penetrating keratoplasty
than DALK (GRADE rating: moderate). The small number of studies included in the review and methodological issues relating to
the two, mean that the overall quality of the evidence in this review is low. There is currently insufficient evidence to determine which
technique may offer better overall outcomes - final visual acuity and time to attain this, keratometric stabilisation, risk of rejection or
failure, or both, and risk of other adverse events - for patients with keratoconus. Large randomised trials comparing the outcomes of
penetrating keratoplasty and DALK in the treatment of keratoconus are needed.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence about the effect of deep anterior lamellar keratoplasty (DALK) (new technique) versus penetrating keratoplasty
(standard technique) in people with keratoconus.
Background
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Keratoconus is a disease of the cornea, which is the clear surface at the very front of the eye. In eyes with keratoconus, the cornea
becomes weak and cannot keep the spherical shape needed to provide “normal” vision. While the majority of people diagnosed with
keratoconus can be treated with rigid contact lenses, in approximately 10% to 15% of patients this treatment is not sufficient and they
require a corneal graft. This may be full-thickness (penetrating) or partial-thickness (lamellar). While the nature of each of these two
types of transplantation suggest pros and cons for both, the clinical and practical outcomes have not previously been systematically
reviewed.
Study characteristics
We included two randomised controlled trials (RCTs) which involved a total of 111 participants in this review. Both trials were
conducted in single medical centres in Iran and compared the outcomes, at least three months post-suture removal (for a minimum of
12 months in the newer study, and for a range of 6.8 to 36.4 months in the older study), of participants with keratoconus who had
received DALK to those who had received penetrating keratoplasty. The evidence is current to October 2013.
Key results
The results suggested that graft rejection is more likely to occur following penetrating keratoplasty, however likelihood of graft failure
was similar in both groups, as were visual and structural results.
DALK was unable to be completed as planned in four cases and in a further three cases complications during dissection required
further intervention. Other adverse events, of varying severity, were reported in both intervention groups. For both types of surgery,
these included postoperative astigmatism (when the cornea is no longer perfectly curved), raised pressure in the eye following steroid
use, and a failure of the epithelium, the front layer of the eye, to heal properly. In recipients of DALK, one participant had interface
neovascularisation (a growth of blood vessels where the host and donor cornea come together) and one had wrinkling of Descemet’s
membrane, a structural element of the cornea. In the penetrating keratoplasty groups, one participant required graft resuturing and one
had an atonic pupil, a condition in which the pupil dilates and is non-reactive. The included studies reported adverse events thoroughly.
Quality of the evidence
The evidence remains weak, as the quality of evidence is rated very low to moderate.
Large trials comparing the outcomes of DALK and penetrating keratoplasty for the treatment of keratoconus, are needed. These should
be randomised single-masked trials, in which graft recipients are unaware of their group allocation. Because of the nature of the surgery,
it is not likely to be possible to conduct double-masked trials as practitioners who are qualified to undertake outcomes assessments
would be able to see which graft a participant had received. Future trials should include regular, long-term follow-up and consistent
methods must be used.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Deep anterior lamellar keratoplasty (DALK) compared with penetrating keratoplasty for keratoconus
Patient or population: Patients with keratoconus undergoing corneal grafting
Settings: Hospital
Intervention: Deep anterior lamellar keratoplasty (DALK)
Comparison: Penetrating keratoplasty
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Penetrating keratoplasty DALK
Postoperative BCVA (3
months) (LogMAR)
No usable data were available on this measure in either of the identified studies
Postoperative functional
BCVA achieved (3
months)
Functional BCVA= vision
of 0.30 LogMAR or better.
As at, 3months post-graft
No usable data were available on this measure in either of the identified studies
Postoperative BCVA (12
months) (LogMAR)
As at, 12 months post-
graft
The mean postoperative
BCVA in the control group
was 0.08 LogMAR
The mean postoperative
BCVA in the intervention
group was 0.06 LogMAR
higher
(95%CI -0.02 to 0.14)
N/A 30 (1) ⊕©©©
very low1
Postoper-
ative BCVA (post-suture
removal, varied follow-
up times) (LogMAR)
As at, at least 3 months
post-suture removal
The mean postoperative
BCVA in the control group
was 0.15 LogMAR
The mean postoperative
BCVA in the intervention
group was 0.03 LogMAR
higher
(95%CI -0.01 to 0.07)
N/A 77 (1) ⊕©©©
very low1
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Postoperative functional
BCVA achieved (post-
suture removal, varied
follow-up times)
Functional BCVA= vision
of 0.30 LogMAR or better
As at, at least 3 months
post-suture removal
670 per 1000 545 per 1000
(92 to 932)
OR 0.59 (0.05 to 6.77) 77 (1) ⊕©©©
very low1
Presence of at least one
rejection episode
As at, post-suture re-
moval
180 per 1000 68 per 1000
(30 to 151)
OR 0.33 (0.14 to 0.81) 111 (2) ⊕⊕⊕©
moderate2
Failed graft
Including caseswhere the
DALK or PK procedure
was unable to be suc-
cessfully completed as
outlined in the methodol-
ogy for the study
In Javadi 2010 4/46 people in the DALK group had failed graft compared to 0/35 in PK group (OR 7.52, 95% 0.39 to 144.43); in Razmju 2011 0/15 people in
DALK group had failed graft compared to 1/15 in PK group (OR 0.31, 0.01 to 8.28)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; BCVA: Best corrected visual acuity; UCVA: Uncorrected visual acuity; LogMAR: Logarithm of the minimum angle of resolution (see footnotes)
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
LogMAR: Each line of a LogMAR chart has 5 letters. Each letter is worth 0.02 on the LogMAR scale. Normal vision (6/6 or 20/20) is a
logMAR score of 0. A person with vision one full line (five letters) worse than normal will score 0.10, while a person with vision one
line better than normal will score -0.10.
Assumed risks for frequency of graft failure, rejection episodes and achievement of functional BCVA in penetrating keratoplasty performed
for keratoconus, are based on figures from the 2012 Australian Corneal Graft Registry report. The assumed risk for achievement of
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functional UCVA is based on the assertion that half of keratoconus patients who undergo penetrating keratoplasty need to wear visual
aids to achieve their BCVA.
1Downgraded for risk of bias, imprecision and inconsistency (not possible to assess consistency as only one small trial).
2Downgraded for risk of bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Keratoconus is an ectatic (weakening) disease of the cornea, which
is the clear surface at the front of the eye (Coster 2002). Weakness
in the tensile strength of the cornea results in distortion of the an-
terior refractive surface of the eye. The weakened cornea is unable
to stand the intraocular pressure and protrudes in a conical shape
(Ertan 2008a). The increased curvature of the conical cornea re-
sults in myopia (short-sightedness), and irregularities of the cone
produce astigmatism, which causes blurred vision.
Keratoconus is usually bilateral and manifests early, in the first
two decades of life (Ertan 2008a; Espandar 2010). Progression is
uncommon after the age of 35 years (Romero-Jimenez 2010). For
most people, progression is slow. Early onset of the condition is
often associated with more rapid progression.
Corneal curvature is used to assess the severity and progression of
keratoconus. Central corneal curvature is adequately measured by
keratometry. More extensive assessment of corneal shape requires
videokeratography (Gobbe 2005; Jafri 2007).
Various systems have been developed to classify the progression of
keratoconus into different stages of the disease (Romero-Jimenez
2010). One such system which is widely accepted and utilised is
the Amsler-Krumeich classification system, separating the disease
into four stages based on level of myopia and astigmatism, cen-
tral keratometric readings, scarring and corneal thickness (Ertan
2008b). A variation on this system has been developed more re-
cently by Alió and Shabayek (Alió 2006) to incorporate diagnostic
information relating to the severity of higher order corneal aberra-
tions, the visual distortion created by a wavefront of light passing
through an irregular eye.
Advanced keratoconus is also accompanied by an increased in-
cidence of hydrops. This is an acute stromal oedema caused by
breaks in Descemet’s membrane through which aqueous humour,
the substance filling the space between the lens and cornea, en-
ters and swells the stroma, the major component of the cornea.
Hydrops generally results in scarring of the cornea, which can
have a continued impact on visual potential (Rabinowitz 1998;
Romero-Jimenez 2010), however it is a rare complication (Bilgin
2009).
Keratoconus is common. It has been reported to affect approx-
imately one person in 2000 in the North American population
(Rabinowitz 1998). Although some suggest that the prevalence
could actually be as high as one per 500 people (Ertan 2008a;
Espandar 2010), other studies have found lower prevalence rates,
sometimes as low as one per 70,000 people. These studies were
conducted in a number of different countries and although the dis-
ease affects all ethnic groups, findings suggest that people of various
ethnic backgrounds, particularly those of Asian descent, may be
more prone to the disease than Caucasian populations (Georgiou
2004). The inconsistency in reported prevalence across studies is
probably also due to the wide range of definitions and diagnostic
criteria utilised by practitioners and researchers (Rabinowitz 1998;
Romero-Jimenez 2010).
The disease affects both men and women, however some studies
have found variations in prevalence across the sexes. Genetics have
been found to play a role in the disease, with a family history re-
ported in approximately 6% to 10% of cases and an increased risk
in first degree relatives also documented. A recent study on kera-
toconus in monozygotic and dizygotic twins supports the premise
that genetic background makes an important contribution to dis-
ease severity, but also suggests an environmental effect on its ex-
pression (Tuft 2012). A review of the genes thus far implicated
in keratoconus has identified at least six coding mutations wor-
thy of further investigation (Wheeler 2012), and new candidate
genes continue to be pulled from genome-wide association studies
(Lu 2013). The definitive cause of keratoconus is still unknown
(Rabinowitz 1998; Wang 2000).
Description of the intervention
The treatment of keratoconus relies on the use of a hard or semi-
rigid contact lens to cover the irregular cornea and provide a
new, appropriately curved anterior refractive surface (Bilgin 2009;
Rabinowitz 1998). If the surface of the conical cornea is too steep
or too irregular to bear a contact lens, or if the eye is too sensitive
to tolerate a lens, surgery becomes necessary; approximately 10%
to 15% of patients diagnosed with keratoconus require surgery
(Rabinowitz 1998; Romero-Jimenez 2010). Corneal transplanta-
tion is the procedure employed. The purpose of corneal transplan-
tation for keratoconus is to replace the abnormal anterior refract-
ing surface of the eye with a donor cornea that has a normal an-
terior surface shape. Corneal transplantation for keratoconus may
be full-thickness (penetrating) or partial-thickness (lamellar).
Penetrating keratoplasty
Penetrating keratoplasty has been performed as a treatment for
keratoconus for over 70 years (Castroviejo 1948) and remains the
leading treatment for those sufferers with contact lens intolerance
(Jhanji 2010; Rabinowitz 1998). Existing longitudinal data show
that keratoconus is one of the most common indications for pene-
trating keratoplasty and that these recipients have higher graft sur-
vival rates than those undergoing the surgery for other conditions
(Jaycock 2008; Williams 2007). An analysis conducted in 2006
concluded that it was a cost-effective treatment for severe cases of
keratoconus (Roe 2008).
Penetrating keratoplasty involves the replacement of a full-thick-
ness portion of the cornea (Coster 2002; Romero-Jimenez 2010).
There are many variations in technique, however a recent review
of the published evidence concluded that there was “no evidence
for the superiority of any specific technique” (Frost 2006).
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Deep anterior lamellar keratoplasty (DALK)
More recently, lamellar transplantation, in which only a partial-
thickness of the cornea is replaced, has been reintroduced as a
surgical treatment for keratoconus (Romero-Jimenez 2010). This
form of transplantation has been used for decades, however poor
visual outcomes resulted in a decline in its use (Trimarchi 2001).
Newer techniques in which the interface of the donor and host is
at the level of Descemet’s membrane have reinvigorated the use of
this form of surgery (Karimian 2010; Sugita 1997).
Deep anterior lamellar keratoplasty (DALK) is frequently used for
keratoconus. Advocates claim that this procedure is preferable to
penetrating keratoplasty for eyes that are free from corneal scarring
or hydrops (Jhanji 2010). The premise is that, because the en-
dothelial cell layer of the recipient is left intact during DALK, the
prospect of endothelial rejection is precluded (Romero-Jimenez
2010; Tan 2010b).
Various techniques have been used to dissect the stroma from
the underlying Descemet’s membrane (Jhanji 2010; Tan 2010b).
Common approaches include manual dissection (Anwar 2002;
Karimian 2010), which may be enhanced by injection of air into
the anterior chamber and stroma (Archila 1984); dissection with
a visco-elastic substance, as advocated by Melles (Melles 2000); or
the big-bubble dissection technique advocated by Anwar et al (
Anwar 2002).Dissectionwith the femtosecond laser is also gaining
some currency (Buzzonetti 2010; Farid 2009). Each approach has
its proponents.
How the intervention might work
To reiterate, the purpose of corneal transplantation for keratoconus
is to replace the abnormal anterior refractive surface of the eye
with a cornea that has a normal shape. In penetrating keratoplasty
the full-thickness of the cornea is replaced, while in DALK the
corneal stroma is replaced down to the Descemet’s membrane,
so that the diseased portion of the eye is still replaced, while the
healthy endothelium of the recipient is left intact.
Why it is important to do this review
While the desired therapeutic outcomes are identical, the benefit
and risk profile of the two procedures may be different and dis-
parate outcomes have been reported. Replacing fewer layers of the
cornea may reduce the likelihood of rejection and subsequent fail-
ure as the endothelium, the layer involved in many incidences of
rejection, is no longer replaced during the surgery. However, other
complications may arise due to problems at the donor/host junc-
tion. Visual outcomes may be affected by this or by the reduction
in time from transplantation to suture removal. It is important
that outcomes from the newer treatment, DALK, be compared
to those achieved using the traditional penetrating technique in
terms of visual outcome and graft survival. The results will help
to inform corneal surgeons and keratoconus sufferers of the ap-
propriateness of each treatment for this condition. This will aid in
the clinical decision making process with regard to the selection
of treatment for individuals with this condition.
O B J E C T I V E S
To compare visual outcomes after deep anterior lamellar kerato-
plasty (DALK) and penetrating keratoplasty for keratoconus, and
to compare additional outcomes relating to factors which may
contribute to poor visual outcomes (e.g. astigmatism, graft rejec-
tion and failure).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that met the
stated inclusion criteria. The review included all RCTs in which
one arm received treatment with penetrating keratoplasty and the
other withDALK.Where a studywas defined as being randomised
but the details were not included in the published literature, we
attempted to gain this information from the authors.
Types of participants
Participants of any age could be included in selected trials. We ex-
cluded studies that included participants with other confounding
related disorders, such as pellucid marginal degeneration (PMD)
(the thinning of the periphery rather than the central area of the
cornea) or keratoglobus in which the entire corneal surface is in-
volved. We only included in the review studies which specified an
objective method of diagnosis of the keratoconus (slit lamp ex-
amination, corneal topography, wave front analysis). Participants
could be at any stage of the disease and there could be a mixture
of stages of progression amongst participants, as long as this was
specified. Participants must not have had a history of corneal scar-
ring or hydrops. With regards to keratoconus prevalence or pro-
gression, no significant differences across cultural and racial back-
grounds have been confirmed in the scientific literature. Thus,
studies from anywhere in the world were eligible for inclusion.
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Types of interventions
We included trials in which the outcomes of penetrating kerato-
plasty and DALK, as treatments for keratoconus, were directly
compared to one another. We also included studies in which both
treatments were compared to one another as well as a third treat-
ment or a control group. We excluded studies comparing either
one of these treatments alone to a third treatment or a control
group.
Types of outcome measures
Studies which reported at least one clinical outcome were eligible
for inclusion.
Primary outcomes
The vast majority of keratoconus patients who undergo corneal
graft surgery do so in order to gain improved vision (Williams
2007). In some cases, uncorrected post-graft visionmay improve to
a functional level but for others, approximately half of recipients,
correction with contact lenses or spectacles will still be necessary
in order to achieve optimal, useful vision. Therefore, we used post-
graft best corrected visual acuity (BCVA) as the primary outcome
measure.
At three months post-graft, the initial healing of the eye should
have concluded and BCVA results start to become more reliable.
Three months was therefore selected as the time point at which
the balance between the likelihood that BCVA results would be
valid were balanced with the need to minimise the likelihood of
attrition bias, and so this time point was selected for the primary
outcome measure.
For inclusion in analyses, BCVA needed to be provided (mean and
range) in terms of either Snellen or LogMARmeasurements (mea-
surements given in either of these two forms can be easily con-
verted into the other for the relevant analyses). Where necessary,
Snellen measurements were converted into LogMAR. LogMAR
measurements were to be obtained using the Bailey-Lovie chart,
not the adapted ETDRS chart, developed as part of the Early
Treatment of Diabetic Retinopathy Study (Kaiser 2009), which
gives a somewhat different result and is not accurate for measuring
visual acuity in people without disorders of the retina.
Where recorded, post-graft BCVA was to be considered in two
ways, firstly in terms of the level of BCVA achieved (functional
vision of 6/12 or better versus non-functional vision of 6/15 or
worse) and also in terms of change frompre-graft BCVA (improve-
ment of >1 line of Snellen acuity, ≤1 line of change in Snellen
acuity in either direction, deterioration of > 1 line of Snellen acu-
ity).
Secondary outcomes
Analyses of BCVA at six months, 12 months and 24 months were
planned as secondary outcomes. Final BCVA is often not achieved
until after all sutures have been removed and the eye has had a
chance to settle. As such, analysis of BCVA at least three months
post-suture removal were also planned as a secondary outcome
measure.
Uncorrected visual acuity (UCVA) was a secondary outcome mea-
sure. Again, it was planned that this would be analysed for mea-
surements at three, six, 12 and 24 months post-surgery, plus at
least threemonths post-suture removal, where provided (mean and
range) in terms of either Snellen or LogMAR measurements. As
with BCVA, these data were to be considered both in terms of the
final UCVA achieved and with regards to the change in UCVA
pre- to post-graft.
We also considered the method of visual correction (in order to be
able to achieve a desirable BCVA) and keratometry readings (to
determine level of astigmatism) as secondary outcome measures.
Other secondary outcome measures were the frequency of rejec-
tion episodes and graft failure.
Timing of outcome assessment
As visual recovery from corneal grafting can continue for a long
time, outcome measures were to be analysed primarily at three
months post-graft; as well as in the context of secondary outcome
measures at the following periods of time post-graft, where possi-
ble: six, 12 and 24 months. In addition, the removal of sutures has
been shown to impact on final visual acuity and so, where avail-
able, comparisons were made between both BCVA and UCVA at
least three months after final suture removal.
We contacted authors in an effort to ascertain these measurements
where they were not given in the published literature.
Adverse outcomes
It was anticipated that other adverse effects may have been re-
ported, including intraoperative complications, such as perfora-
tion or need for re-bubbling, and postoperative events such as
scarring, infection, cataract or pain. All adverse events reported
were considered important. The frequency of these events was also
compared across treatment groups in a qualitative manner.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes and
Vision Group Trials Register) (2013, Issue 9), the Database of
Abstracts of Reviews of Effects (DARE) (2013, Issue 9), Ovid
MEDLINE, Ovid MEDLINE In-Process and Other Non-In-
dexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE
(January 1946 to October 2013), PubMed (1966 to October
2013), EMBASE (January 1980 to October 2013), Latin Ameri-
can and Caribbean Health Sciences Literature Database (LILACS)
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(January 1982 to October 2013), OpenGrey, Web of Science -
Science Citation Index (SCI) (January 1970 to October 2013),
Health Collection - Informit (January 1977 to October 2013),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or lan-
guage restrictions in the electronic searches for trials. We last
searched the electronic databases on 31 October 2013.
See: Appendices for details of search strategies for CENTRAL
and DARE (Appendix 1), MEDLINE (Appendix 2), PubMed
(Appendix 3), EMBASE (Appendix 4), LILACS (Appendix 5),
CINAHL (Appendix 5), OpenGrey (Appendix 7), SCI (Appendix
8), Informit (Appendix 9), mRCT (Appendix 10), ClinicalTri-
als.gov (Appendix 11) and the ICTRP (Appendix 12).
Searching other resources
We handsearched the following international conference proceed-
ings in order to identify further, unpublished studies.
1. American Society of Cataract and Refractive Surgery
Symposium and Congress: 2007 to 2012
2. Asia Pacific Academy of Ophthalmology Congress: 2012
3. European Society of Cataract and Refractive Surgeons
Congress: 2009 to 2012
4. International Congress of Eye Research: 2012
5. Royal Australian and New Zealand College of
Ophthalmology Congress: 2011 to 2012
6. Royal College of Ophthalmologists Congress: 2011 to 2012
7. World Ophthalmology Congress: 2008 to 2012
We attempted to contact the authors of any studies identified in
this way to gain further information where this was required.
We also handsearched the reference lists of selected studies in order
to identify other relevant articles, conference presentations or book
chapters.
Data collection and analysis
Selection of studies
Two review authors (MK and KW) independently assessed all cita-
tions gathered using the outlined parameters. Each independently
classified each citation as either ’definitely not relevant’ or ’poten-
tially relevant’. Where a study was judged by both authors at this
time to be ’definitely not relevant’, it was excluded from further
analysis. In cases where one author believed a study to be ’definitely
not relevant’ while the other classified it as ’potentially relevant’
the final classification of the study was determined by consensus.
Where citations were classified as ’potentially relevant’, full copies
of related publications were obtained by MK and each study was
assigned an identification number (ID). Where a study published
in a language other than English was identified as being poten-
tially relevant, we initially arranged a translation of the methods
and results sections of the study. If the study appeared to meet the
selection criteria based on themethods and results, we then sought
a full English translation of the study. Where the published data
were felt by at least one author (either MK or KW) to be insuffi-
cient to determine the relevance of the study, MK contacted the
trial investigators to request the necessary further information.
Having read the full articles and considered any further informa-
tion gathered from trial investigators, the two review authors (MK
and KW) classified them as either ’relevant’ or ’not relevant’. These
authors compared both lists, and excluded those that were classi-
fied as ’not relevant’ by both review authors. The reasons for their
exclusion were recorded and these are documented in the review.
Those that were classified as ’relevant’ by both review authors were
included in the review. We recorded the reasons for any further
exclusions and documented them in the review. MK entered data
into RevMan (RevMan 2012) at each step in the review process.
Data extraction and management
Two review authors (MK and KW) independently extracted the
data using a form based on one developed by the Cochrane Eyes
and Vision Group. This included information on the following.
1. The age, gender, race, geographical location and grade of
keratoconus of the participants, as well as the number in each
treatment group and the comparability of the two groups on the
aforementioned parameters at baseline.
2. The methods used in each intervention group.
3. Information on missing data and participants who did not
complete the trial.
4. The outcomes of the treatments. We collected dichotomous
data in terms of number at risk and number of events, and used
means and standard deviations for continuous data. We extracted
data for the outcome measures outlined for this review.
MK entered the data into RevMan (RevMan 2012), with KW
checking the entered data for inconsistencies or errors. Where
there were missing data, we identified this, along with any reasons
given, and we conducted analysis utilising the available data.
Assessment of risk of bias in included studies
Two authors (MK and KW) independently assessed the risk of
bias for the included studies as per the methods given in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Methodological quality was assessed for the fol-
lowing parameters.
Potential issues relating to selection bias
1.Randomisation technique: randomisation via a random num-
ber generator, random number table, shuffled cards or shuffled
envelopes, where the assignment of treatment groups is conducted
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and confirmed prior to specific participant allocation and cannot
be changed after this point, was considered appropriate. Inade-
quate techniques included alternation, assignment based on vari-
ables such as record numbers, dates of birth or days of the week,
or any form of randomisation in which participant assignment
could be altered or affected by the treating surgeon after the initial
assignment. We excluded studies with inadequate randomisation
techniques and recorded the reasons for this.
2. Allocation concealment: we considered methods such as central
telephone randomisation and numbered, sealed, opaque envelopes
as adequate methods of concealing the allocation from people
recruiting participants.
Potential issues relating to performance bias
3 Blinding/masking: recipients should ideally be masked.
Potential issues relating to detection bias
4. Outcome measurements: despite differences in the techniques,
outcomes of the interventions should be measured in the same
way for both. Those administering the assessments of outcomes
should ideally be masked.
Potential issues relating to attrition bias
5. Completion of follow-up: was this equal across treatment
groups, what were the reasons for this and were there adequate
numbers remaining for the results to be meaningful?
Two review authors (MK and KW) graded the studies on each
of these five parameters, providing a determination of low risk
of bias, unclear risk of bias, or high risk of bias. They discussed
any disagreements in classification. If necessary, the authors of the
trials in question were contacted by MK in an attempt to clarify
any unclear information.
Measures of treatment effect
Outcome measures comprised two types of data: continuous and
dichotomous. We used mean differences to ana lyze continuous
data (BCVA and UCVA measured in LogMAR, as well as change
in BCVA and UCVA LogMAR results). For outcomes with di-
chotomous data (functional level of BCVA or UCVA, rejection
episodes, graft failure), we measured the effect size using the odds
ratio (OR).
Unit of analysis issues
There were no unit of analysis issues because people were ran-
domised to treatment andone eye included in the included studies.
Future updates of this review may include trials that include both
eyes, either as within-person studies, or where both eyes receive
the same treatment. We will address these issues as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011), especially in light of the fact that keratoconus may
not be bilaterally symmetrical and outcome in one eye may affect
outcome in the other. See also Differences between protocol and
review.
Dealing with missing data
We considered the potential impact of any missing data. While
Javadi 2010 did have missing data, no intention-to-treat (ITT)
analyses were possible as data for the missing cases were not avail-
able. We documented the cases lost to follow-up in this study and
reported the available case analysis. We discussed the likely impact
of these missing data in the text and we rated the study as being
at high risk of attrition bias.
Assessment of heterogeneity
We assessed the heterogeneity of the included studies in order to
determine whether it was appropriate to carry out a meta-analysis
on the data. This was done by examining the characteristics of
the studies and the forest plot of study results, and by conduct-
ing a Chi² test of statistical heterogeneity and determining the I²
statistic. Where the I² statistic indicated less than 30% variabil-
ity due to heterogeneity, this was considered to be insubstantial,
while over 50%was considered to indicate substantial heterogene-
ity. For cases in which 30% to 50% heterogeneity was estimated,
we considered the magnitude and direction of the effect, as well as
the P value of the Chi² test, when making a final decision about
the substantiality. For the outcomes where we determined that the
heterogeneity of the studies was substantial, we did not combine
the results in ameta-analysis but rather reported them in a descrip-
tive summary. Where substantial heterogeneity was not present,
we conducted meta-analyses using the fixed-effect model, as only
a small number of studies were included.
Assessment of reporting biases
In order to assess bias relating to selective outcome reporting, we
compared the intended outcome measures for each included trial,
as recorded in the methods sections of resulting articles, to those
reported in the results sections.
Data synthesis
For the majority of outcome measures, we identified an insuffi-
cient number of trials to conduct meta-analyses, and so we have
provided results in a descriptive summary form. Data were avail-
able from two studies for the outcome measures of “presence of
rejection episodes” and “failed graft” and so we examined these re-
sults usingmeta-analyses as well as presenting them in a descriptive
summary form. We used fixed-effect models as we only identified
two studies.
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Subgroup analysis and investigation of heterogeneity
In cases where we determined heterogeneity of the studies to be
significant, we decided not to combine the results in a meta-anal-
ysis, but rather report them in a descriptive summary. We judged
heterogeneity to be substantial with regards to the variable “failed
graft” and so judged the quantitative analysis of the data from the
two studies to be unreliable, and we provided a descriptive sum-
mary instead.
Sensitivity analysis
We conducted one sensitivity analysis, in which we removed the
data from the Razmju 2011 study, as the risk of allocation bias -
encompassing issues related to the randomisation process, includ-
ing sequence generation and allocation concealment - was judged
to be high. In this way, it was possible to assess how strongly the
results of our review are related to the decisions and assumptions
that we have made throughout the review process.
Methods for creating Summary of Findings tables
In Summary of findings for the main comparison, we presented
data for seven outcome measures. Firstly, the primary outcome
measures of BCVA and achievement of functional BCVA, at three
months post-graft. As the primary outcome of interest was BCVA,
we then included outcomes relating to BCVA at other time points
that were reported in either of the studies, these being BCVA
achieved 12 months post-graft and three months post-suture re-
moval, and achievement of functional BCVA post-suture removal.
In addition, we included the two outcomes for which data were
available from both studies, presence of rejection and graft failure.
We did not include outcomes for BCVA at 12 months post-graft
in Summary of findings 2 as these data were not given in the Javadi
2010 paper.
For the two continuous outcome measurements included in the
’Summary of findings’ table forwhich datawere available (BCVAat
12months post-graft andBCVApost-suture removal) the assumed
risk was the mean value in the penetrating keratoplasty group,
while the corresponding risk was the mean value in the DALK
group. For the three dichotomous outcomes (graft failure, rejection
episodes and achievement of functional BCVA) we calculated the
assumed risk based on figures from the 2012 Australian Corneal
Graft Registry report (Williams 2012). We based the correspond-
ing risks (and 95% confidence intervals) for the DALK group on
the assumed risk in the comparison group (ACR) and the relative
effect (OR) of the intervention (and its 95% CI) in that corre-
sponding risk (CR) = 1000*((OR*ACR)/(1-ACR+(OR*ACR))).
Two review authors (MK and KW) independently evaluated the
quality of evidence using theGRADE system, as outlined inChap-
ter 8 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Deeks 2011).
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 206 references (Figure
1). The Trials Search Co-ordinator scanned the search results, re-
moved duplicates and removed 95 references which were not rel-
evant to the scope of the review. We screened the remaining 72
records from the electronic search, and we also found a further
five records identified through handsearching of conference pro-
ceedings, resulting in 77 records to be screened. We excluded 31
records as not relevant after evaluation of their abstract.
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Figure 1. Results from searching for studies for inclusion in the review.
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We assessed 39 full-text articles, five abstracts from conference
proceedings and two unpublished trials identified via ClinicalTri-
als.gov for eligibility.
We judged 37 full-text articles and two conference abstracts as not
eligible for inclusion and so we excluded them with reasons doc-
umented. After several attempts to contact the authors of three of
the unpublished trials identified from the conference proceedings,
we were unable to source any further information on these stud-
ies and therefore excluded them also. We were unable to obtain
contact details for the authors of one of the trials registered on
ClinicalTrials.gov and so excluded this.
We identified two additional potentially relevant articles (Jiang
2006; Liu 2008) in the reference list of one of the screened arti-
cles. These articles are both in Chinese and are currently awaiting
classification, pending full translation. See the Characteristics of
studies awaiting classification table for further information.
One unpublished trial (NCT01901614) meets the inclusion cri-
teria for this review, but is still in the recruitment phase and is thus
categorized as ongoing.
Two studies met all eligibility criteria and we included them in the
qualitative synthesis and meta-analyses. However, details of the
randomisation procedure were unavailable for one of these studies
and so we conducted sensitivity analysis to determine the effect
this might have on the overall findings.
Included studies
We included two studies that met our inclusion criteria (Javadi
2010; Razmju 2011). We also conducted a sensitivity analysis in
which we removed the data from the Razmju 2011 study and
considered the data in the Javadi 2010 study alone to see what
impact this might have on the results and conclusions.
Study design
Both studies were randomised single centre trials, with participants
allocated to receive either penetrating keratoplasty orDALK.Only
one eye of each participant was treated as part of the trials.
Participants
Both studies were conducted in Iran. Razmju 2011 included 30
participants, with 15 allocated to each treatment group, while
Javadi 2010 included 81 participants, with 46 undergoing DALK
and 35 penetrating keratoplasty. Participants had moderate to se-
vere keratoconus pre-operatively.
Interventions
Details of the specific interventions usedwere not given byRazmju
2011, with their trial report simply stating that one arm of the
study received penetrating keratoplasty, and the other deep lamel-
lar keratoplasty.
Javadi 2010 conducted DALK using the big-bubble technique
with the recipient cornea trephined 7.75 mm or 8 mm, depend-
ing on the recipients vertical corneal diameter (greater than or
equal to versus less than 10.5 mm). Air was injected into the mid-
stroma to form a big-bubble extending to the trephination site.
The stroma was then removed. In penetrating keratoplasty, the
recipient trephination size (7.75 mm or 8 mm) was again depen-
dent on the recipients vertical corneal diameter (greater than or
equal to versus less than 10.5 mm). Trephination was conducted
with a Hessburg-Barron suction trephine and the excision was
completed using right and left corneal scissors. For these donor
corneas, trephination was conducted from the endothelial side. In
all surgeries, the size of the corneal donor button was dependent
on the recipient trephine size and was 0.25 mm or 0.5 mm larger,
depending on vitreous length (greater than or equal to versus less
than 16 mm). The donor cornea was sutured to the recipient in
one of three different ways, all using 10-0 nylon sutures: 16 inter-
rupted sutures, one single 16- to 18-bite running suture, or a sin-
gle 16-bite running suture plus an 8-bite interrupted suture. This
was based on surgeon preference and the condition of the eye. Su-
ture tension was adjusted via intraoperative keratoscopy. Cefazolin
100 mg and betamethasone 4 mg were injected subconjunctivally.
Participants received topical chloramphenicol every six hours for
30 days and topical betamethasone 0.1% every six hours, tapered
over two to three months.
Outcome measures
Razmju 2011 reported outcomes relating to the level achieved and
change from postoperative levels for both BCVA and spherical
equivalent. They also reported on intraoperative and postoperative
complications, including rejection and failure. Outcomes were
measured at 12 months.
Javadi 2010 reported outcomes on measures of visual acuity
(UCVA, BCVA) and refraction (spherical equivalent, keratomet-
ric astigmatism). They also reported on intraoperative and post-
operative complications (failure and rejection). Follow-up exami-
nations were performed at one, three, seven and 30 days; three, six
and 12 months; and three to six months after complete suture re-
moval. Outcome data were provided regarding overall failure and
rejection rates. Outcomes post-suture removal (variable follow-
up lengths) were given for keratometric astigmatism (final level
and change from postoperative), spherical equivalent (final level
and change from postoperative), and final BCVA. Graphs showed
results for BCVA, UCVA, spherical equivalent and keratometric
astigmatism pre-operatively, at one, three, six, 12 and 24 months,
and at a minimum three months post-suture removal. The major-
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ity of these data were not specified in-text, and so the exact figures
at each time-point are uncertain.
Excluded studies
We excluded 30 studies (Acar 2013; Akdemir 2012; Amayem
2013; Arenas 2005; Behrens 2000; Birnbaum 2008; Borderie
2012; Busin 1991; Cardoso da Silva 2007; Cohen 2010; Farias
2008; Funnell 2006;Hara 2013;Haugen 2001; Javadi 2006; Jiang
2011; Jones 2009; Koo 2011; Kubaloglu 2012; McDonald 1987;
Motlagh 2012; Panda 1999; Salvetat 2013; Sari 2012; Serdarevic
1996; Shimmura 2005; Shoja 2007; Tan 2010a; Watson 2004;
Yamaguchi 2011) relating to 32 papers because they were not
RCTs. We excluded a further four papers (Frost 2006; Reinhart
2011; Shi 2012; Tan 2007) as they turned out to be review arti-
cles rather than original studies. We excluded three studies (Panda
2012; Kandemir 2011; Mahjoub 2011), all identified via hand-
searching of conference proceedings, as it was unclear whether
they were RCTs and what, if any, exclusions of participants were
undertaken. In each case, we attempted to contact the authors of
these studies to gather further information, a minimum of two
times, without success. One study (Cheng 2011), for which there
were two published articles and two conference abstracts available,
appears to meet all criteria except that only a subgroup of partic-
ipants had keratoconus. Communication with the study authors
suggests that data for this subgroup only may be available, how-
ever it has not been provided as yet and so we have excluded this
study at this time, but we could include it in future updates if the
data become available. We excluded one study (NCT00371202)
registered on ClinicalTrials.gov, as it was unclear whether the trial
was completed and we were unable to obtain contact details for
the study author.
Risk of bias in included studies
The assessed risk of bias of the included studies is shown graphi-
cally in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Random sequence generation
Both studies reported that the participants were randomly allo-
cated to the twogroups. Razmju 2011 didnot specify theirmethod
of randomisation and we therefore judged this study to have an
unclear risk of bias. Javadi 2010 indicated that they used a random
number table and therefore we judged their study to have a low
risk of bias.
Allocation concealment
No information was provided by Razmju 2011 or Javadi 2010
about whether there was adequate allocation concealment (though
Javadi 2010 did reveal that the random allocation was carried out
at the same clinic where the surgery was performed) and therefore
there was unclear risk of bias for both studies.
Blinding
Due to the differences in the two treatments being studied, it is not
possible to mask surgeons to which procedure is being performed.
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No information was provided by Razmju 2011 or Javadi 2010
about whether participants or follow-up personnel were masked.
It was also not stated whether follow-up was conducted by the
surgeons themselves, or others. Thus the risk of bias was judged
to be high for both studies in terms of masking of participants
and personnel, and unclear with regards to masking of outcome
assessment.
Incomplete outcome data
For Razmju 2011, it appears that all outcome data are based on
the 30 participants reported to have been included in the study
and therefore we deemed risk of bias to be low for this factor.
Data for four eyes in the DALK group were excluded from sev-
eral of the follow-up analyses in Javadi 2010 because of failed air
injection. The exclusion of these four participants from the out-
comes relating to post-suture removal measurements of visual and
refractive outcomes has the potential to have skewed the data. The
outcomes for these participants would be likely to be negative if no
further treatmentwas undertaken, and this would bias the findings
in favour of the DALK group. However, it is not specified within
the paper what further treatments these participants went on to
have, and it is highly likely that they underwent an alternative or
additional grafting procedure. It is therefore possible that they had
positive outcomes due to these further treatments. No intention-
to-treat (ITT) analyses incorporating the results from these four
participants were conducted by Javadi 2010 and it was not possi-
ble to conduct them as part of this review due to a lack of available
data for the four missing cases. Although all participants (except
the four excluded at the time of surgery) completed a minimum
three-month post-suture removal follow-up, there was great vari-
ation in the length of follow-up reported. Therefore, we judged
the study to be at high risk of attrition bias.
Selective reporting
Results for all participants appear to be reported in both Razmju
2011 and Javadi 2010, though in both cases it is unclear whether
the outcome measures reported were what was planned, as a pro-
tocol is not available for either study. Therefore, we judged the
risk of selective reporting bias to be unclear for both studies.
Other potential sources of bias
We did not detect any other potential sources of bias in either
study.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2 Summary of findings - Javadi findings only
All data included in the review were from published sources. Cor-
respondence with the authors did not result in the provision of
further usable unpublished data at this time.
Each included study only had each outcomemeasure reported on a
single scale. Razmju 2011 only presented data for 12 months post-
graft. While Javadi 2010 made reference to results at three, six,
12 and 24 months in their figures, usable data were only available
for three or more months post-suture removal. We made efforts to
obtain further data from the authors, however we did not receive
any. We presented all usable data from both included studies in
this review.
Primary outcome
Neither of the included studies reported data relating to the pri-
mary outcome measure of the review, BCVA at three months
post-graft. Javadi 2010 appeared to have this data as they showed
“changes in BCVA” at threemonths within their Figure 1, however
a request to the authors for this information in a usable format did
not result in provision of the data.
Secondary outcomes
Javadi 2010 reported post-suture removal outcomes for 77 of their
81 randomised participants. Data on these 77 participants were
available for each of the visual and refractive outcomes mentioned
below. In the other four participants, the initial operation did not
proceed as planned. As this review aimed to compare the effective-
ness of each technique, these grafts were treated as a graft failure
for the purpose of analysis. As such, data were available with re-
gards to the outcomes “failed graft” and “presence of at least one
rejection episode” for all 81 recipients. Other adverse events were
reported for the 77 participants who underwent the planned pro-
cedure. Razmju 2011 reported 12 month postoperative outcomes
for all 30 of their participants on each of the outcomes mentioned
below.
Visual acuity outcomes
With regards to secondary outcomes relating to visual acuity,
Razmju 2011 reported a significant improvement in BCVA in
both groups 12 months following surgery, however there was no
significant difference in this change between the two groups with
a small estimate of effect that crossed the line of no difference
(mean difference (MD) 0.06 LogMAR, 95% CI -0.02 to 0.14;
Analysis 1.1), indicating no superiority of either technique at this
time. Javadi 2010 also found a non-significant difference in the
BCVA of participants in each intervention group at their final,
post-suture removal, follow-up, with a small estimate of effect that
crossed the line of no difference (MD 0.03 LogMAR, 95% CI -
0.01 to 0.07; Analysis 1.2). A comparison of the changes from
pre-graft was not given at this time point. The percentages of
participants reporting functional best corrected vision (>= 20/40)
at this time, were also not significantly different across groups
(odds ratio (OR) 0.59, 95% CI 0.05 to 6.77; Analysis 1.3). There
was also a non-significant estimate of effect across groups in the
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Javadi 2010 study at the final follow-up for UCVA (MD 0.09
LogMAR, 95% CI -0.07 to 0.25; Analysis 1.4). The percentage
of participants reporting functional uncorrected vision (>= 20/40)
at this time, was also not significantly different across groups (OR
1.48, 95% CI 0.58 to 3.81; Analysis 1.5).
Refractive outcomes
Javadi 2010 reported no significant differences in mean kerato-
metric astigmatism across groups, at least three months post-su-
ture removal, and we found a non-significant estimate of effect
(MD 0.47D, 95% CI -1.36 to 0.42; Analysis 1.6). No significant
differences were found by Javadi 2010 pre-operatively or at one,
three, six, 12, or 24 months follow-up. No significant differences
in spherical equivalent across groups at any time point (pre-op-
eration, one, three, six, 12, 24 months or three months post-su-
ture removal) were observed, with a non-significant estimate of
effect at least three months post-suture removal (MD0.60D, 95%
CI -1.52 to 0.32; Analysis 1.7). Razmju 2011 reported improve-
ments on measurements of both astigmatism and spherical equiv-
alent, measured in dioptres (D), in both intervention groups at 12
months. A comparison of the improvement across the two inter-
vention groups showed no significant difference for either spheri-
cal equivalent, or astigmatism, with a non-significant estimate of
effect for either (MD 0.69D, 95% CI -1.19 to 2.57; Analysis 1.8,
MD 1.26D, 95% CI -0.88 to 3.40; Analysis 1.9). Neither study
reported on the methods of visual correction used by participants
to achieve BCVA at any time point.
Adverse events
With regards to adverse events, Razmju 2011 reported four cases of
endothelial rejection in the penetrating keratoplasty group, three
of which resolved with steroid treatment and one of which ended
in graft failure. They also reported a case of stromal rejection in
one participant who had received a DALK, which was successfully
treated with steroids. Javadi 2010 reported 11 cases of endothelial
rejection in the penetrating keratoplasty group, and four cases of
subepithelial rejection. All cases resolved with steroid treatment.
There were also 10 cases of subepithelial rejection in the DALK
group which were also successfully treated with steroids. Our anal-
yses showed a significant estimate of effect, with rejection just a
third as likely to result from a DALK procedure than a penetrating
keratoplasty (P = 0.02, OR 0.33, 95% CI 0.14 to 0.81; Analysis
1.10).
Razmju 2011 reported no intraoperative complications in either
group. Javadi 2010 reported that in four planned DALK proce-
dures, the eyes required manual dissection to Descemet’s mem-
brane due to failed air injection. It is unclear whether these par-
ticipants still went on to undergo a DALK or if their surgery had
to be converted to a penetrating keratoplasty, however the surg-
eries could be considered a technical failure and their results were
excluded from all analyses of visual and keratometric outcomes.
There was no significant difference in the likelihood of techni-
cal failure across groups in this study (OR 7.52, 95% CI 0.39 to
144.43; Analysis 1.11). No postoperative failures were reported
in this study, while one was reported in the Razmju 2011 study.
There was no significant difference in the likelihood of postoper-
ative failure (OR 0.31, 95% CI 0.01 to 8.28; Analysis 1.11). A
meta-analysis was not conducted on these data due to significant
heterogeneity between the two studies.
With respect to other complications, Razmju 2011 reported
a case of interface neovascularisation in one DALK partici-
pant.Descemet’s membrane was perforated in three cases in the
DALK group in the Javadi 2010 study, resulting in double cham-
ber formation in two eyes. In one case this resolved spontaneously
while the other required treatment with an intracameral air in-
jection. It is not stated what happened in the third case. Javadi
2010 reported nine cases of intolerable postoperative astigmatism
requiring refractive surgery, five in the DALK group and four in
the penetrating keratoplasty group. There were two cases in each
group of steroid induced ocular hypertension. Five participants in
the DALK group and two in the penetrating keratoplasty group
suffered from persistent epithelial defects. In the DALK group,
one participant also had wrinkling of Descemet’s membrane. In
the penetrating keratoplasty group, one participant required graft
resuturing and one had an atonic pupil, a condition in which the
pupil dilates and is non-reactive.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Deep anterior lamellar keratoplasty (DALK) compared with penetrating keratoplasty for keratoconus
Patient or population: Patients with keratoconus undergoing corneal grafting
Settings: Hospital
Intervention: Deep anterior lamellar keratoplasty (DALK)
Comparison: Penetrating keratoplasty
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Penetrating keratoplasty DALK
Postoperative BCVA (3
months) (LogMAR)
Measured on LogMar
scale where normal vi-
sion is 0.00. Each line
of a LogMAR chart has
5 letters. Each letter is
worth 0.02 on the Log-
MAR scale. A person with
vision one full line (five
letters) worse than nor-
mal will score 0.10, while
a person with vision one
line better than normal will
score -0.10
As at, 3months post-graft
N/A N/A N/A N/A N/A No usable data were
available on this measure
in the identified study
Postoperative functional
BCVA achieved (3
months)
Functional BCVA= vision
of 0.30 LogMAR or better.
N/A N/A N/A N/A N/A No usable data were
available on this measure
in the identified study
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As at, 3months post-graft
Postoper-
ative BCVA (post-suture
removal, varied follow-
up times)
Measured on LogMar
scale where normal vi-
sion is 0.00. Each line
of a LogMAR chart has
5 letters. Each letter is
worth 0.02 on the Log-
MAR scale. A person with
vision one full line (five
letters) worse than nor-
mal will score 0.10, while
a person with vision one
line better than normal will
score -0.10
As at, at least 3 months
post-suture removal
The mean postoperative
BCVA in the control group
was 0.15 LogMAR
The mean postoperative
BCVA in the intervention
group was 0.03 LogMAR
higher
(95%CI -0.01 to 0.07)
N/A 77 (1) ⊕©©©
very low1,2,3
Postoperative functional
BCVA achieved (post-
suture removal, varied
follow-up times)
Functional BCVA= vision
of 0.30 LogMAR or better.
As at, at least 3 months
post-suture removal
Study population OR 0.59 (0.05 to 6.77) 77 (1) ⊕©©©
very low1,2,3
670 per 1000 545 per 1000
(92 to 932)
Presence of at least one
rejection episode
As at, at least 3 months
post-suture removal
Study population OR 0.37 (0.14 to 0.98) 81 (1) ⊕⊕©©
low1,3
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180 per 1000 75 per 1000
(30 to 177)
Failed graft
Including caseswhere the
DALK or PK procedure
was unable to be suc-
cessfully completed as
outlined in the methodol-
ogy for the study
As at, at least 3 months
post-suture removal
Study population OR 7.52 (0.39 to 144.43) 81 (1) ⊕©©©
very low1,3,4
33 per 1000 204 per 1000
(13 to 831)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; BCVA: Best corrected visual acuity; UCVA: Uncorrected visual acuity; LogMAR: Logarithm of the minimum angle of resolution
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Assumed risks for frequency of graft failure, rejection episodes and achievement of functional BCVA in penetrating keratoplasty performed
for keratoconus, are based on figures from the 2012 Australian Corneal Graft Registry report. The assumed risk for achievement of
functional UCVA is based on the assertion that half of keratoconus patients who undergo penetrating keratoplasty need to wear visual
aids to achieve their BCVA.
1Not specified whether allocation concealment and blinding was used for either participants or outcome assessors.
2Incomplete data analysed. High risk of attrition bias as the outcomes from the four failed grafts were likely to be poor.
3Inability to assess consistency due to inclusion of just one trial.
4Very wide confidence interval, suggesting an imprecise estimate, which crosses the line of no difference (OR 7.52, 95% CI 0.39 to
144.43).
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D I S C U S S I O N
Summary of main results
Noevidencewas availablewith regards to the effect of deep anterior
lamellar keratoplasty (DALK) versus penetrating keratoplasty on
best corrected visual acuity (BCVA) at three months post-surgery.
The evidence of the review suggests that both DALK and pene-
trating keratoplasty are successful in improving BCVA, spherical
equivalent and keratometric astigmatism of patients with kerato-
conus at the time points of 12 months post-surgery and at least
three months post-final suture removal. The review did not find
any evidence for a significantly better result from either procedure
based on the data from the two studies included.
Instances of graft rejection were more frequent in participants un-
dergoing penetrating keratoplasty in both included studies. The
majority of these complications were resolved with steroid treat-
ment.
Graft failure was reported in one penetrating keratoplasty recip-
ient in Razmju 2011, while four intended DALK recipients had
to undergo an adjusted procedure, and three others experienced
tearing of Descemet’s membrane in Javadi 2010.
Other adverse events, of varying severity, were reported in both in-
tervention groupswith similar frequency. For both types of surgery,
these included postoperative astigmatism, steroid induced ocular
hypertension and persistent epithelial defects. Individual cases of
neovascularisation and wrinkling of Descemet’s membrane were
reported in DALK recipients, while the need for graft resuturing
and atonic pupil, a condition in which the pupil dilates and is
non-reactive, were reported following penetrating keratoplasty.
Overall completeness and applicability of
evidence
The included studies failed to address the main objective of the
review, to evaluate the quality of BCVA three months post-graft.
While information on post-graft BCVA were available in both
studies, these data were only available at 12 months follow-up in
Razmju 2011 and at various time points post-suture removal in
Javadi 2010. Razmju 2011 did not address the question of the
number of participants who achieved functional levels of vision
post-graft. Data on the primary outcome measure of BCVA at
three months post-graft were shown in a graph in Javadi 2010;
however, the number of participants achieving functional BCVA
and themean BCVA achieved by each group at this point, with the
corresponding P value for the difference between the two groups in
terms of the change from pre-operative levels, were not given. The
same issues were present for the secondary outcomemeasurements
of UCVA, spherical equivalence and astigmatism.
Both studies provided adequate information on the number of
rejection episodes and graft failures, plus any other adverse events,
at least three months post-suture removal.
The low number of identified studies, the lack of data relating
to the primary outcome measure and the inability to confirm the
randomisation technique used inRazmju 2011, reduced the ability
to conduct quantitative synthesis. Further studies are needed, to
increase the completeness and applicability of the evidence. The
available evidence does however suggest that rejection episodes are
more likely to occur in penetrating keratoplasty procedures. From
an ethical perspective, researchersmay need to discuss this possible
increased risk with any patients included in future studies which
aim to compare outcomes from the two techniques, and highlight
the need to balance this risk with the need to determine whether
other outcomes (visual and keratometric) are comparable.
Quality of the evidence
Overall, the quality of the evidence is rated as very low to moder-
ate, with methodological limitations, incomplete data analysis and
imprecision of findings leading to the results being downgraded
in the Summary of findings for the main comparison A sensi-
tivity analysis, in which the findings of Javadi 2010 alone were
considered in order to assess the impact that the potential lack of
adequate randomisation in Razmju 2011 may have had, resulted
in evidence rated very low to low, as shown in the Summary of
findings 2. Removing the results of Razmju 2011 in the sensitivity
analysis did not result in a large change to the findings with regards
to rejection episodes. However, the findings with regards to failed
grafts were heterogeneous between the two included studies, and
removing the Razmju 2011 data resulted in a higher correspond-
ing risk for DALK. This has a very wide 95% CI, suggesting an
imprecise estimate, which crosses the line of no difference (OR
7.52, 95% CI 0.39 to 144.43). The quality of evidence for these
outcomes was judged to be low for presence of rejection episodes
and very low for graft failure, primarily because the inclusion of
just one trial led to an inability to assess consistency. It does not
appear that inclusion of Razmju 2011 biased the results with re-
gards to rejection episodes, however it may have done so for failure
rates.
Methodological quality
The review included two studies, both conducted in Iran. One
study (Javadi 2010) was well designed, conducted and reported,
and was of moderate methodological quality. No ITT analyses
were undertaken, creating a high risk of attrition bias. This study
randomised participants through an eligible manner but did not
specify whether allocation was concealed from people recruiting
participants to the trial.
The second study (Razmju 2011) was rated as having poor
methodological quality. While stating that it was randomised, the
authors provided no details of the randomisation technique em-
ployed and also did not specify whether allocation concealment
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was undertaken. It appears that all participants completed follow-
up, so attrition bias was rated as low risk. A sensitivity analysis was
undertaken to see whether the inclusion of this study impacted
on the results of the quantitative analysis. Removal of these results
appeared to impact the findings with regards to graft failure, re-
sulting in a higher corresponding risk for DALK. However, this
had a very wide 95% CI, suggesting an imprecise estimate. Re-
moval of these data did not change the findings regarding rejection
episodes.
Treatment
Javadi 2010 was clear about the techniques used, so that the ap-
plicability of the results to this review was confirmed.
Razmju 2011 did not give specifics of the operative techniques
used.These can vary greatly, particularly forDALKprocedures and
so the lack of this information also lowers the level of confidence
that can be had in the applicability of the evidence from this trial
to the review.
Outcomes
The small number of eligible studies identified and the poor appli-
cability of the outcomes reported in both included studies, meant
that there was inadequate evidence to be able to evaluate and com-
pare the effectiveness of the two interventions.
Potential biases in the review process
We consider that the search strategies used to identify relevant
studies were adequate, with a wide range of databases and ad-
ditional grey literature reviewed. However, we also acknowledge
that we identified one potentially relevant trial (for which we were
unable to obtain contact information for the study co-ordinator),
and several unpublished, potentially relevant trials, for which our
requests for further information from the authors did not receive
replies.Why these trials are unpublished remains unclear, and thus
bias due to the exclusion of data from these studies is possible. Due
to the identification of just two trials to include in the review, we
were unable to use a funnel plot to investigate publication bias.
The review of each potential study for relevance by two review au-
thors, independently, reduced the risk that relevant studies would
be excluded due to personal bias or human error on the part of the
review authors. Likewise, the independent extraction of data from
the included studies by the two review authors, and the review of
the final included results by all review authors, reduced the risk of
bias in these steps of the process.
Agreements and disagreements with other
studies or reviews
The review by Reinhart 2011 identified 11 non-randomised (case-
control, cohort and case series) studies, which compared DALK
and penetrating keratoplasty for any indication (not specifically
for keratoconus). Their conclusions were that the two techniques
lead to equivalent outcomes in terms of BCVA and refractive mea-
surements. The present review found insufficient evidence to form
conclusions regarding the comparison of outcomes from the two
techniques for these outcome measures.
The review by Shi 2012 included three studies which they iden-
tified as RCTs, as well as eight non-randomised (two case-control
and six cohort) studies, comparing the results of DALK and pen-
etrating keratoplasty for keratoconus. One of the RCTs identified
was that of Javadi 2010. They did not identify Razmju 2011. The
other two RCTs identified were Liu 2008 and Jiang 2006. We
are still awaiting full translation of the articles relating to these
two studies, and are yet to confirm that they were appropriately
randomised for inclusion in the present review. The conclusions
of Shi 2012, based on the results of the three randomised studies,
were that penetrating keratoplasty lead to greater improvement
in BCVA, that there were no significant differences in the out-
comes relating to refractive measurements, and that DALK lead
to a significantly lower likelihood of rejection. This conclusion
regarding rejection is in agreement with the findings of the present
review. The present review found insufficient evidence to form
conclusions surrounding the comparison of outcomes from the
two techniques regarding improvement in BCVA and refractive
measurements.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found no evidence to support a difference in outcomes with
regards to BCVA, either three months post-graft or at any other
time point included in the review, in participants undergoing ei-
ther DALK or penetrating keratoplasty for keratoconus.
We found some evidence, of low tomoderate quality, that rejection
is more likely to occur in this population following penetrating
keratoplasty than DALK.
We found no evidence to support a difference in outcomes with
regards to graft survival, final UCVA or keratometric outcomes.
There is currently insufficient evidence to determine which tech-
nique may offer better overall outcomes - final visual acuity and
time to attain this, keratometric stabilisation, risk of rejection or
failure, or both, and risk of other adverse events - for patients with
keratoconus.
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Implications for research
Large randomised trials, comparing the outcomes of penetrat-
ing keratoplasty and DALK in the treatment of keratoconus, are
needed. Necessary sample sizes to detect a clinically significant dif-
ference between the two groups should be calculated and utilised
in the trial design. Selection criteria need to be consistent and re-
ported, including the method of diagnosis used. People receiving
the intervention for an indication other than keratoconus should
not be included in the trial. Randomisation procedures need to
be acceptable and reported. Details of the interventions need to
be documented and reported. Recipients need to be masked to
the intervention administered and this should be reported. Be-
cause of the nature of the surgery, it is not likely to be possible to
conduct double-masked trials as practitioners who are qualified to
undertake outcomes assessments would be able to see which graft
a participant had received. Outcome measures need to include:
rates of rejection and failure, visual outcomes, refractive outcomes,
and adverse events. Planned comparisons need to be documented
and carried out, with intention-to-treat (ITT) analyses applied in
instances where participants have missing data. Follow-up should
be at regular time periods, with follow-up extending to at least 12
months, or threemonths post-suture removal, whichever is longer.
Appropriate analyses need to be utilised to compare the data across
both groups and time periods. Baseline data for participants needs
to be reported and any differences across groups controlled for in
analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Javadi 2010
Methods Randomised comparative clinical trial in a single private clinic in Iran. Randomisation
based on a random number table
Participants 81 eyes of 81 participants: 46 undergoing DALK and 35 undergoing penetrating ker-
atoplasty. All 81 had data available with regards to graft failure and presence of rejec-
tion episodes. Four DALK recipients were excluded from analyses relating to visual and
refractive outcomes as they failed to achieve bared Descemet’s membrane, leaving 42
DALK recipients and 77 total recipients in these analyses. Age and gender breakdown
are provided only for these 77 recipients. DALK: 29 males, 13 females; mean age = 26.
91 ± 7.9 years, range 15-44; penetrating keratoplasty: 28 males, 7 females; mean age =
30.89 ± 10.3 years, range 17-50. Study dates not reported, but pre-2009
Interventions DALKwas conducted using the big-bubble techniquewith the recipient cornea trephined
7.75 mm or 8 mm, depending on the recipients’ vertical corneal diameter (greater than
or equal to versus less than 10.5 mm). Air was injected into the mid-stroma to form a
big-bubble extending to the trephination site. The stroma was then removed
In penetrating keratoplasty, the recipient trephination size (7.75 mm or 8mm) was again
dependent on the recipients’ vertical corneal diameter (greater than or equal to versus less
than 10.5mm). Trephenation was conducted with a Hessburg-Barron suction trephine
and the excision was completed using right and left corneal scissors. For these donor
corneas, trephination was conducted from the endothelial side
In all surgeries, the size of the corneal donor button was dependent on the recipient
trephine size and was 0.25 mm or 0.5mm larger depending on vitreous length (greater
than or equal to versus less than 16 mm). The donor cornea was sutured to the recipi-
ent in one of three different ways, all using 10-0 nylon sutures: 16 interrupted sutures,
one single 16- to 18-bite running suture, or a single 16-bite running suture plus an 8-
bite interrupted suture. This was based on surgeon preference and the condition of the
eye. Suture tension was adjusted via intraoperative keratoscopy. Cefazolin 100 mg and
betamethasone 4 mg were injected subconjunctivally. Subjects received topical chloram-
phenicol every six hours for 30 days and topical betamethasone 0.1% every six hours,
tapered over two to three months
Follow-up examinations were performed at 1, 3, 7 and 30 days; 3, 6, 12 and 24 months;
and 3-6 months after complete suture removal
Outcomes Primary outcomes:
• Visual outcomes (UCVA, BCVA)
• Refraction (spherical equivalent, keratometric astigmatism)
• Contrast sensitivity function
• Wave front aberrometry
• Central corneal thickness
Secondary outcomes:
• Intraoperative complications (including conversion)
• Postoperative complications (including failure and rejection)
Specific outcome information regarding number of grafts with rejection episodes, attain-
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Javadi 2010 (Continued)
ment of BCVA/UCVA of 20/40 and mean keratometric astigmatism, was provided at 3-
6 months after complete suture removal. Data for some visual outcomes and refraction
were shown at 3, 6, 12 and 24 months as well as post-suture removal within figures, but
not referred to in-text, with no specific measurements provided
Notes Some secondary procedures (e.g. resuturing) were carried out in some subjects
Study conducted by the Ophthalmic Research Centre at Shahid Beheshti University. No
financial support or conflicts of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation based on a “random num-
ber table”
Allocation concealment (selection bias) Unclear risk Randomisation occurred in the private
clinic where the surgery was carried out. It
is unclear whether the allocation was con-
cealed from staff recruiting participants to
the trial
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was impossible to mask the surgeon to
which surgery was being conducted. It is
unclear whether participants were masked
to which surgery they underwent
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear who conducted the outcome
assessment or whether they were aware of
group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Four eyes were excluded from the DALK
group because of failed air injection. The
outcomes data for these four eyes were ex-
cluded from follow-up analyses. This may
skew the results in favour of DALK as the
outcomes for these participants were more
likely to be negative. There was great vari-
ation in follow-up length, though all par-
ticipants (except the four excluded at time
of surgery) completed 6 month follow-up
Selective reporting (reporting bias) Unclear risk Unclear if outcome measures are what was
planned as protocol not available
Other bias Unclear risk Not mentioned
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Razmju 2011
Methods Randomised single centre trial conducted at a hospital in Iran. Method of randomisation
not stated
Participants Consecutive participants at a single hospital in Iran. 15 assigned to receive penetrating
keratoplasty and 15 assigned to receive DALK. DALK: 3 males, 12 females, Mean age =
29.4 ± 2.3 years; penetrating keratoplasty: 5 males, 10 females; Mean age = 30.9 ± 4.1
years. Age range for all participants = 20-40 years. The data were collected from 2009-
2011
Interventions Details of the specific interventions used were not given, with their paper simply stating
that one arm of the study received penetrating keratoplasty and the other deep lamellar
keratoplasty
Follow-up was conducted at 12 months post-graft
Outcomes Primary outcomes:
• BCVA (achieved and change)
• Spherical equivalent (achieved and changed)
• Time to suture removal
Secondary outcomes:
• Intraoperative complications (including conversion)
• Postoperative complications (including failure and rejection)
Outcome data were provided at 12 months regarding number of grafts with rejection
episodes, mean BCVA, change in BCVA from baseline, mean keratometric astigmatism
and mean spherical equivalent
Notes This paper was published in Farsi and was translated by one of the review authors (MZ)
Study funded and conducted as part of a medical doctorate at the Isfahan Univeristy of
Medical Sciences. No conflicts of interest declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The randomisation technique is not speci-
fied
Allocation concealment (selection bias) Unclear risk No information is provided about whether
there was adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information is provided about whether
participants or personnel were masked. It
would not be possible to mask the surgeon
to which treatment was being given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information is provided about whether
the investigators conducting the outcome
assessment were masked
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Razmju 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appears that data from all 30 enrolled
participants are included in the outcome
measures reported
Selective reporting (reporting bias) Unclear risk Results for all participants appear to be re-
ported. Unclear if outcome measures are
what was planned as protocol not available
Other bias Unclear risk Not mentioned
BCVA: best corrected visual acuity
DALK: deep anterior lamellar keratoplasty
UCVA: uncorrected visual acuity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acar 2013 Not an RCT
Akdemir 2012 Not a RCT
Amayem 2013 Not a RCT
Arenas 2005 Not a RCT
Behrens 2000 No DALK group
Birnbaum 2008 NoDALK group, not just participants with keratoconus, no exclusion of participants with hydrops/scarring
Borderie 2012 Not a RCT, no exclusion of participants with comorbid eye conditions, no exclusion of participants with
hydrops/scarring
Busin 1991 Not a RCT
Cardoso da Silva 2007 Not a RCT, no exclusion of participants with hydrops/scarring
Cheng 2011 Only a subgroup of the included population (15 in each group) had keratoconus, with the remainder having
a mixture of other presenting diseases. Data on this keratoconus subgroup requested from authors but yet
to be received
Cohen 2010 Not a RCT
Farias 2008 No penetrating keratoplasty group
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(Continued)
Frost 2006 Review article, not original research
Funnell 2006 Not a RCT
Hara 2013 Not a RCT
Haugen 2001 Not a RCT, no exclusion of participants with comorbid eye conditions, no exclusion of participants with
hydrops/scarring
Javadi 2006 No DALK group, no exclusion of participants with hydrops/scarring
Jiang 2011 Not a RCT
Jones 2009 Not a RCT, no exclusion of participants with hydrops/scarring
Kandemir 2011 Unclear if it was a RCT, or whether exclusions were undertaken. No response from author to enquiries
Koo 2011 Not a RCT, no exclusion of participants with hydrops/scarring
Kubaloglu 2012 Not a RCT
Mahjoub 2011 Unclear if it was a RCT, or whether exclusions were undertaken. No response from author to enquiries
McDonald 1987 No DALK group
Motlagh 2012 Not a RCT
NCT00371202 Unclear if completed. No results available. No response from author to enquiries
Panda 1999 Not a RCT, no exclusion of participants with comorbid eye conditions, no exclusion of participants with
hydrops/scarring
Panda 2012 Unclear if it was a RCT, or whether exclusions were undertaken. No response from author to enquiries
Reinhart 2011 Review article, not original research
Salvetat 2013 Not a RCT
Sari 2012 Unclear if it was a RCT, or whether exclusions were undertaken. No response from author to enquiries
Serdarevic 1996 Quasi-randomised trial, no DALK group, no exclusion of participants with hydrops/scarring
Shi 2012 Review article, not original research
Shimmura 2005 Not a RCT, no penetrating keratoplasty group
Shoja 2007 No DALK group, no exclusion of participants with hydrops/scarring
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Tan 2007 Review article, not original research
Tan 2010a Not a RCT
Watson 2004 Not a RCT, no exclusion of participants with comorbid eye conditions
Yamaguchi 2011 Not a RCT, no exclusion of participants with comorbid eye conditions, no exclusion of participants with
hydrops/scarring
DALK: deep anterior lamellar keratoplasty
RCT: randomised controlled study
Characteristics of studies awaiting assessment [ordered by study ID]
Jiang 2006
Methods Described as “randomised” but methods not described
Participants 58 eyes of 47 participants: 30 undergoing DALK and 28 undergoing penetrating keratoplasty. Unclear whether results
were reported for all participants. Mean age is provided for each group - DALK: 28.6 years, penetrating keratoplasty:
31 years. The study time-frame was 2001-04. Participants were followed for a median of 28 months in the DLK
group and 36 months in the penetrating group
Interventions Details not clear
Outcomes Primary outcomes
• Visual outcomes (change in BCVA)
• Refraction (spherical equivalent, keratometric astigmatism)
Secondary outcomes
• Postoperative complications (including failure and rejection)
Notes Only abstract available in English. Awaiting full translation from Chinese
Liu 2008
Methods Not clear
Participants 48 eyes of 48 participants: 23 undergoing DALK and 25 undergoing penetrating keratoplasty. Unclear whether
results were reported for all participants
Interventions Details not clear
Outcomes Primary outcomes
• Visual outcomes (BCVA)
Secondary outcomes
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Liu 2008 (Continued)
• Postoperative complications (including failure and rejection)
Notes Only abstract available in English. Awaiting full translation from Chinese
BCVA: best corrected visual acuity
DALK: deep anterior lamellar keratoplasty
Characteristics of ongoing studies [ordered by study ID]
NCT01901614
Trial name or title OCT-guided LALAK for KCN
Methods Randomised comparative clinical trial in a single private hospital in Portland, Oregon, USA. Block randomi-
sation by independent statistician based on a random number table
Participants Estimated enrolment of 48
Interventions Laser assisted lamellar anterior keratoplasty (LALAK): A dovetail shaped cut will be made on the donor cornea
tissue using femtosecond laser, proportional in depth to the central stromal thickness, and the section of
cornea to be grafted then separated from the stroma, stored in preservation media and shipped to the surgeon.
Topical anaesthesia is given to the recipient and a matching femtosecond laser cut will be made in the host
cornea allowing the donor portion to be inserted in a tongue-in-groove manner. The graft is sutured in place
and a protective eye shield placed in the eye. Intralase-enabled keratoplasty (IEK): A full-thickness graft is
prepared from donor tissue using zigzag side cuts. The section of cornea to be grafted is then separated from
the rim, stored in preservation media and shipped to the surgeon. Topical anaesthesia is given to the recipient
and a matching femtosecond laser cut will be made in the host cornea creating a bridge 70-100 microns in
size for the donor button to rest on. The graft is sutured in place and a protective eye shield placed in the eye
Outcomes Primary outcomes
• Visual outcomes (BCVA)
Starting date August 2013
Contact information Janice Ladwig: ladwig@ohsu.edu; Denny Romfh: romfhd@ohsu.edu
Notes Estimated completion date 2016
BCVA: best corrected visual acuity
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D A T A A N D A N A L Y S E S
Comparison 1. Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Postoperative BCVA (12
months) (LogMAR)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Postoperative BCVA (varied
follow-up times, post-suture
removal) (LogMAR)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Postoperative functional BCVA
achieved (varied follow-up
times, post-suture removal)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Postoperative UCVA (varied
follow-up times, post-suture
removal) (LogMAR)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Postoperative functional UCVA
achieved (varied follow-up
times, post-suture removal)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Postoperative keratometric
astigmatism (varied follow-up
times, post-suture removal) (D)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Postoperative spherical
equivalent (varied follow-up
times, post-suture removal) (D)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Postoperative keratometric
astigmatism (12 months) (D)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Postoperative spherical
equivalent (12 months) (D)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Presence of at least one rejection
episode
2 111 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.14, 0.81]
11 Failed graft 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 1 Postoperative BCVA (12 months) (LogMAR).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 1 Postoperative BCVA (12 months) (LogMAR)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Razmju 2011 15 0.14 (0.15) 15 0.08 (0.06) 0.06 [ -0.02, 0.14 ]
-0.5 -0.25 0 0.25 0.5
Favours DALK Favours PK
Analysis 1.2. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 2 Postoperative BCVA (varied follow-up times, post-suture removal) (LogMAR).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 2 Postoperative BCVA (varied follow-up times, post-suture removal) (LogMAR)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Javadi 2010 42 0.18 (0.08) 35 0.15 (0.1) 0.03 [ -0.01, 0.07 ]
-0.5 -0.25 0 0.25 0.5
Favours DALK Favours PK
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Analysis 1.3. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 3 Postoperative functional BCVA achieved (varied follow-up times, post-suture removal).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 3 Postoperative functional BCVA achieved (varied follow-up times, post-suture removal)
Study or subgroup DALK PK Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Javadi 2010 40/42 34/35 0.59 [ 0.05, 6.77 ]
0.001 0.01 0.1 1 10 100 1000
Favours PK Favours DALK
Analysis 1.4. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 4 Postoperative UCVA (varied follow-up times, post-suture removal) (LogMAR).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 4 Postoperative UCVA (varied follow-up times, post-suture removal) (LogMAR)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Javadi 2010 42 0.64 (0.3) 35 0.55 (0.4) 0.09 [ -0.07, 0.25 ]
-0.5 -0.25 0 0.25 0.5
Favours DALK Favours PK
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Analysis 1.5. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 5 Postoperative functional UCVA achieved (varied follow-up times, post-suture removal).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 5 Postoperative functional UCVA achieved (varied follow-up times, post-suture removal)
Study or subgroup DALK PK Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Javadi 2010 17/42 11/35 1.48 [ 0.58, 3.81 ]
0.001 0.01 0.1 1 10 100 1000
Favours PK Favours DALK
Analysis 1.6. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 6 Postoperative keratometric astigmatism (varied follow-up times, post-suture removal) (D).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 6 Postoperative keratometric astigmatism (varied follow-up times, post-suture removal) (D)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Javadi 2010 42 3.89 (2.2) 35 4.36 (1.8) -0.47 [ -1.36, 0.42 ]
-4 -2 0 2 4
Favours DALK Favours PK
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Analysis 1.7. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 7 Postoperative spherical equivalent (varied follow-up times, post-suture removal) (D).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 7 Postoperative spherical equivalent (varied follow-up times, post-suture removal) (D)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Javadi 2010 42 -2.91 (1.7) 35 -2.31 (2.3) -0.60 [ -1.52, 0.32 ]
-4 -2 0 2 4
Favours PK Favours DALK
Analysis 1.8. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 8 Postoperative keratometric astigmatism (12 months) (D).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 8 Postoperative keratometric astigmatism (12 months) (D)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Razmju 2011 15 3.91 (2.7) 15 3.22 (2.55) 0.69 [ -1.19, 2.57 ]
-20 -10 0 10 20
Favours DALK Favours PK
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Analysis 1.9. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 9 Postoperative spherical equivalent (12 months) (D).
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 9 Postoperative spherical equivalent (12 months) (D)
Study or subgroup DALK PK
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Razmju 2011 15 -2.23 (2.66) 15 -3.49 (3.28) 1.26 [ -0.88, 3.40 ]
-10 -5 0 5 10
Favours PK Favours DALK
Analysis 1.10. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 10 Presence of at least one rejection episode.
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 10 Presence of at least one rejection episode
Study or subgroup DALK PK Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Javadi 2010 10/46 15/35 78.1 % 0.37 [ 0.14, 0.98 ]
Razmju 2011 1/15 4/15 21.9 % 0.20 [ 0.02, 2.02 ]
Total (95% CI) 61 50 100.0 % 0.33 [ 0.14, 0.81 ]
Total events: 11 (DALK), 19 (PK)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours DALK Favours PK
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Analysis 1.11. Comparison 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty
(PK), Outcome 11 Failed graft.
Review: Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
Comparison: 1 Deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK)
Outcome: 11 Failed graft
Study or subgroup DALK PK Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Javadi 2010 (1) 4/46 0/35 7.52 [ 0.39, 144.43 ]
Razmju 2011 0/15 1/15 0.31 [ 0.01, 8.28 ]
0.001 0.01 0.1 1 10 100 1000
Favours DALK Favours PK
(1) Grafts failed at surgery. Not included in further analyses.
A P P E N D I C E S
Appendix 1. CENTRAL and DARE search strategy
#1 MeSH descriptor Keratoconus
#2 keratocon*
#3 ectatic* or ectasia
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Keratoplasty, Penetrating
#6 (penetrating or perforating) near/2 (keratoplast*)
#7 full near/3 thickness near/3 cornea*
#8 (#5 OR #6 OR #7)
#9 deep anterior lamellar keratoplast*
#10 deep lamellar keratoplast*
#11 partial near/3 thickness near/3 cornea*
#12 big near/2 bubble
#13 DALK
#14 (#9 OR #10 OR #11 OR #12 OR #13)
#15 (#4 AND #8 AND #13)
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Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp Keratoconus/
14. keratocon$.tw.
15. (ectatic$ or ectasia).tw.
16. or/13-15
17. Keratoplasty, Penetrating/
18. ((penetrating or perforating) adj2 keratoplast$).tw.
19. (full adj3 thickness adj3 cornea$).tw.
20. or/17-19
21. deep anterior lamellar keratoplast$.tw.
22. deep lamellar keratoplast$.tw.
23. (partial adj3 thickness adj3 cornea$).tw.
24. (big adj2 bubble).tw.
25. DALK.tw.
26. or/21-25
27. 16 and 20 and 26
28. 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. PubMed search strategy
(((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomized OR randomly OR placebo[tiab])
OR (trial[ti]) OR (“Clinical Trials as Topic”[MeSH Major Topic])) NOT ((“Animals”[Mesh]) NOT (“Humans”[Mesh] AND “An-
imals”[Mesh]))) AND (((keratoconus[MeSH Terms]) OR (keratocon*) OR (ectatic* OR ectasia)) AND ((keratoplasty, penetrat-
ing[MeSH Terms]) OR (keratoplast*) OR (DALK)))
Appendix 4. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
43Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp keratoconus/
34. keratocon$.tw.
35. (ectatic$ or ectasia).tw.
36. or/33-35
37. exp penetrating keratoplasty/
38. ((penetrating or perforating) adj2 keratoplast$).tw.
39. (full adj3 thickness adj3 cornea$).tw.
40. or/37-39
41. deep anterior lamellar keratoplast$.tw.
42. deep lamellar keratoplast$.tw.
43. (partial adj3 thickness adj3 cornea$).tw.
44. (big adj2 bubble).tw.
45. DALK.tw.
46. or/41-45
47. 36 and 40 and 46
48. 32 and 47
Appendix 5. LILACS search strategy
keratocon$ and keratoplast$ or DALK
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Appendix 6. CINAHL (EBSCO) search strategy
S7 S3 AND S6
S6 S4 OR S5
S5 DALK
S4 keratoplasty or keratoplasties
S3 S1 OR S2
S2 ectatic or ectasia
S1 Keratoconus
Appendix 7. OpenGrey search strategy
keratoconus and keratoplasty
Appendix 8. Web of Science SCI search strategy
#9 #7 AND #8
#8 TS=random*
#7 #3 AND #6
#6 #4 OR #5
#5 TS=DALK
#4 TS=keratoplasty
#3 #1 OR #2
#2 TS=ectatic
#1 TS=keratoconus
Appendix 9. Health Collection (Informit) search strategy
SUBJECT=(keratoconus) AND SUBJECT=(keratoplasty)
Appendix 10. metaRegister of Controlled Trials search strategy
keratoconus AND keratoplasty
Appendix 11. ClinicalTrials.gov search strategy
Keratoconus AND Keratoplasty
Appendix 12. ICTRP search strategy
keratoconus AND keratoplasty
45Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: KW, DC
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Screening search results: MK, KW
Appraising quality of papers: MK, KW
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Data collection for the review: MK, KW
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Analysis of data: MK, KW
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• National Institute of Health Research (NIHR), UK.
Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the
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of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. MZ joined the author team for the review.
2. Despite our efforts we were unable to obtain the conference proceedings for the following conferences to handsearch.
• American Society of Cataract and Refractive Surgery Symposium and Congress: pre-2007
• Asia Pacific Academy of Ophthalmology Congress: pre-2012
• Cambridge Ophthalmological Society Meeting: any
• European Society of Cataract and Refractive Surgeons Congress: pre-2009
• International Congress of Eye Research: pre-2012
• Royal Australian and New Zealand College of Ophthalmology Congress: pre-2011
• Royal College of Ophthalmologists Congress: pre-2011
• World Cornea Congress: any
• World Ophthalmology Congress: pre-2008
3. In our methodology, the sentence “We only included in the review studies which specified a reliable method of diagnosis of the
keratoconus (slit lamp examination, corneal topography, wave front analysis)” was changed to “We only included in the review studies
which specified an objective method of diagnosis of the keratoconus (slit lamp examination, corneal topography, wave front analysis)”
as we felt that “reliable” was a subjective word, and the classification of types of diagnosis as being “reliable” would be difficult to argue.
4. The seven points outlined under the “assessment of risk of bias” section of the protocol were condensed into five points that better
reflected the risk of bias assessment guidelines outlined in theCochraneHandbook and removed points that were actually factors relating
to the inclusion criteria for the studies in the review, rather than the risk of bias (inclusion and exclusion criteria and methodology of
keratoconus grading).
5. We made a slight change to the way that BCVA and UCVA outcomes needed to be reported, as the outline in our protocol did not
accurately reflect the ways in which visual acuity data can, and should, be reported in terms of Snellen lines or LogMAR.
6. We had said that studies for which the randomisation procedure was not clear would be excluded from meta-analyses. Following
reviewer feedback we felt that this was not the best course of action as it removed potentially relevant information from the review. We
chose rather, to include them in meta-analyses, but to also conduct sensitivity analyses to determine whether the results of these studies
affect the overall results of the review.
7. We changed the title of our review from “Penetrating keratoplasty versus deep anterior lamellar keratoplasty for treating keratoconus”
to “Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus” as it was felt that this better reflected
that the outcomes from DALK were being compared to those for penetrating keratoplasty, which is the more established form of
treatment for keratoconus.
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8. It was planned that if the two authors assessing the citations for inclusion of studies in the review could not reach an agreement, a
third author would be consulted. There were no instances where this was necessary and so a third author was not involved in these
decisions. Similarly, following assessment of the full text articles, no studies were classified as ’relevant’ by one author and ’not relevant’
by the other, thus reference to a third author was not necessary or utilised. Finally, a third author was also to be consulted to resolve
any disagreements between the two review authors (MK and KW) regarding the data entered into RevMan. No reference to a third
review author was necessary and so this was not done.
9. Regarding outcome measures, where BCVA and UCVA were provided in terms of Snellen acuity, we had planned to transform these
figures into LogMAR measurements for the purposes of these analyses. Both included studies reported BCVA and UCVA in LogMAR
and so this was not necessary.
10. Where multiple studies were identified with data available on a common continuous variable, we had planned to assess the data
relating to this variable to determine if it was skewed, as outlined in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2011). If this was present we would then consider transformation of the data prior to inclusion in a meta-analysis.
As no continuous variables had data available for more than one included study, transformation was not necessary.
11. All unit of analysis issues were to be dealt with in the manner specified in Chapter 9 of the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2011). As keratoconus is a bilateral condition, it was possible that some trials would involve one eye of each
participant to be assigned to one treatment group (penetrating keratoplasty or DALK) and the other to the other treatment group and
then the overall outcomes compared. Providing that adequate randomisation occurred in terms of which eye was assigned to which
treatment group and all participants had both eyes included in the study, such studies would still meet the criteria for the review as these
surgeries would be performed at different times. These trials were still eligible to be included in the analysis, with attention intended
to be paid to this issue during sensitivity analysis. Neither of the included studies had subjects for which both eyes were included in
the study and so this did not need to be done.
12. Where large amounts of data were missing, we planned to conduct intention-to-treat (ITT) analyses, where possible, to determine
if this had had a significant impact on the results. If it was determined that it did have, the study would be excluded from further
analyses. As Javadi 2010 was the only study identified with data available on the outcome measures for which data were missing, it was
not possible to conduct sensitivity analyses to see if this impacted on the results.
13. We did not conduct any meta-analyses using the random-effects model as only a small number of studies were identified.
14. A funnel plot and sensitivity analysis were to be used to assess publication bias but, due to the low number of studies identified,
this was not possible.
15. It was planned that, where reported in the same trials, we would conduct subgroup analyses for the two main DALK surgical
techniques: the big-bubble and theMelles. These analyses would determine whether the heterogeneity of the overall review was affected
by the differences between these two techniques. Neither of the two trials identified involved multiple DALK surgical techniques, and
so we did not conduct this subgroup analysis.
16. Additional sensitivity analyses were planned in which analyses would be re-run on the data in which: 1) any trials for which the
risk on any parameter was judged to be high were removed, 2) any trials that were funded by industry were removed, and 3) trials
which are unpublished were removed. In this way, it would be possible to assess how strongly the results of our review are related to
the decisions and assumptions that we have made throughout the review process. No trials fitting these criteria were included and so
no such analysis was conducted.
In addition, it was also possible that some studies may have entered all eyes meeting the inclusion criteria into the study (including
two eyes of one participant) and then randomised all of the eyes to a treatment group. This would mean that the same treatment may
be received in both eyes of the same participant, or that some participants may have both eyes included in the trial while others have
just one. The outcomes of corneal graft surgery in one eye have been shown to impact the outcomes of corneal graft surgery in the
other eye of the same individual (Williams 2010). As such, the impact of multiple results from the same individual, whether they were
in the same or different groups, need to be controlled for during analyses. If this had not been done, a sensitivity analysis was to be
conducted, in which these trials would be removed, to check that this did not have a significant impact on the results. No trials fitting
these criteria were included and so no such analysis was conducted.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Corneal Transplantation [∗methods]; Graft Rejection [drug therapy]; Keratoconus [∗surgery]; Keratoplasty, Penetrating [∗methods];
Randomized Controlled Trials as Topic; Steroids [therapeutic use]
MeSH check words
Humans
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